CA2363486A1 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol - Google Patents
Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol Download PDFInfo
- Publication number
- CA2363486A1 CA2363486A1 CA002363486A CA2363486A CA2363486A1 CA 2363486 A1 CA2363486 A1 CA 2363486A1 CA 002363486 A CA002363486 A CA 002363486A CA 2363486 A CA2363486 A CA 2363486A CA 2363486 A1 CA2363486 A1 CA 2363486A1
- Authority
- CA
- Canada
- Prior art keywords
- lipg
- composition
- patient
- cholesterol
- vectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholester ol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the tryacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
Claims (65)
1. A composition for lowering the expression of the LIPG gene in a patient comprising an antisense nucleic acid.
2. The composition of Claim 1 comprising an expression vector which includes said antisense nucleic acid..
3. The composition of Claim 2 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.
4. The composition of Claim 1 wherein said composition is a synthetic antisense nucleic acid.
5. The composition of Claim 4 wherein said antisense nucleic acid is an oligonucleotide.
6. The composition of Claim 5 wherein said oligonucleotide contains chemically modified bases.
7. A composition for lowering the enzymatic activity of the LIPG polypeptide in a patient comprising a neutralizing antibody capable of binding to the LIPG
polypeptide and lowering its enzymatic activity.
polypeptide and lowering its enzymatic activity.
8. The composition of Claim 7 comprising an expression vector including a DNA sequence encoding said antibody.
9. The composition of Claim 8 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.
10. A composition for lowering the enzymatic activity of the LIPG polypeptide in a patient comprising an intracellular binding protein.
11. The composition of Claim 10 comprising an expression vector including a DNA sequence encoding said intracellular binding protein.
12. The composition of Claim 11 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.
13. A composition comprising an inhibitor capable of inhibiting the enzymatic activity of the LIPG polypeptide in a patient.
14. A composition comprising an inhibitor capable of lowering the expression of the LIPG gene in a patient.
15. A composition capable of lowering the expression of LIPG in a patient comprising a ribozyme.
16. The composition of Claim 15 comprising an expression vector including a DNA sequence encoding said ribozyme.
17. The composition of Claim 16 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpesviral vectors, and naked DNA vectors.
18. The composition of Claim 14 wherein said ribozyme is a hammerhead ribozyme.
19. A composition for increasing the level of LIPG
polypeptide in a patient comprising an expression vector including a DNA sequence encoding the LIPG polypeptide.
polypeptide in a patient comprising an expression vector including a DNA sequence encoding the LIPG polypeptide.
20. A composition for increasing the level of LIPG
polypeptide in a patient comprising an LIPG polypeptide and a pharmaceutically acceptable carrier.
polypeptide in a patient comprising an LIPG polypeptide and a pharmaceutically acceptable carrier.
21. A composition for increasing the level of LIPG
polypeptide in a patient comprising an enhancer capable of increasing the expression of the LIPG gene.
polypeptide in a patient comprising an enhancer capable of increasing the expression of the LIPG gene.
22. A composition for increasing the enzymatic activity of LIPG polypeptide in a patient comprising an enhancer which binds to and enhances the enzymatic activity of the LIPG
polypeptide.
polypeptide.
23. A method for raising the level of high density lipoprotein (HDL) cholesterol and apolipoprotein AI in a patient comprising administering to said patient a composition which lowers the enzymatic activity of LIPG in said patient.
24. The method of Claim 23 wherein said composition lowers the level of LIPG polypeptide in a patient.
25. The method of Claim 23 wherein said composition comprises an antisense nucleic acid.
26. The method of Claim 25 wherein said antisense nucleic acid is a synthetic antisense nucleic acid.
27. The method of Claim 26 wherein said antisense nucleic acid is modified to increase the chemical stability of said nucleic acid.
28. The method of Claim 23 wherein said composition comprises a neutralizing antibody capable of binding to the LIPG polypeptide and lowering its enzymatic activity.
29. The method of Claim 23 wherein said composition comprises an inhibitor which inhibits the enzymatic activity of LIPG polypeptide.
30. The method of Claim 29 wherein said inhibitor comprises a compound which lowers the expression of the LIPG
gene.
gene.
31. The method of Claim 23 wherein said composition comprises a ribozyme which cleaves mRNA encoding LIPG.
32. The method of Claim 23 wherein said composition comprises a DNA molecule and a liposome.
33. The method of Claim 32 wherein said liposome is a cationic liposome.
34. The method of Claim 23 wherein said composition comprises DNA and a pharmaceutically acceptable carrier.
35. The method of Claim 23 wherein said composition comprises an expression vector.
36. The method of Claim 35 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors and adeno-associated viral vectors, herpesvirus vectors, and naked DNA vectors.
37. The method of Claim 35 wherein said expression vector includes a DNA sequence which encodes a ribozyme.
38. The method of Claim 36 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors and adeno-associated viral vectors, herpesvirus vectors, and naked DNA vectors.
39. The method of Claim 35 wherein said expression vector includes a DNA sequence which encodes an antisense nucleic acid.
40. The method of Claim 35 wherein said expression vector includes a DNA sequence which encodes a neutralizing antibody which binds LIPG.
41. The method of Claim 35 wherein said expression vector includes a DNA sequence which encodes an intracellular binding protein which is capable of binding and neutralizing LIPG.
42. The method of Claim 41, wherein said intracellular binding protein is an antibody.
43. The method of Claim 35 wherein said expression vector includes a DNA sequence which encodes an inhibitory molecule which inhibits the enzymatic activity of LIPG.
44. The method of Claim 23 further comprising administration of a composition capable of expressing apolipoprotein AI in said patient.
45. A method for lowering the level of very low density lipoprotein (VLDL) cholesterol in a patient comprising administering to said patient a composition capable of increasing the enzymatic activity of LIPG in said patient.
46. The method of Claim 45 wherein said composition is an LIPG polypeptide and a pharmaceutically acceptable carrier.
47. The method of Claim 46 wherein said composition is an expression vector capable of expressing an LIPG
polypeptide.
polypeptide.
48. The method of Claim 47 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, and adeno-associated viral vectors.
49. The method of Claim 45 wherein said composition comprises an enhancer which enhances the enzymatic activity of LIPG polypeptide.
50. The method of Claim 45 wherein said composition comprises an enhancer which increases expression of the LIPG
gene.
gene.
51. A method for lowering the level of low density lipoprotein (LDL) cholesterol in a patient comprising administering to said patient a composition capable of increasing the enzymatic activity of LIPG in said patient.
52. The method of Claim 51 wherein said composition is an LIPG polypeptide and a pharmaceutically acceptable carrier.
53. The method of Claim 52 wherein said composition is an expression vector capable of expressing an LIPG
polypeptide.
polypeptide.
54. The method of Claim 53 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, and adeno-associated viral vectors.
55. The method of Claim 53 wherein said composition comprises an enhancer which enhances the enzymatic activity of LIPG polypeptide.
56. The method of Claim 53 wherein said composition comprises an enhancer which increases the expression of the LIPG gene.
57. A method for lowering the level of LDL cholesterol in a patient comprising administering to the patient an enhancer which preferentially enhances the enzymatic reactions between LIPG polypeptide and LDL cholesterol relative to the enzymatic reactions between LIPG polypeptide and HDL cholesterol and apolipoprotein AI.
58. A method for lowering the level of VLDL cholesterol in a patient comprising administering to the patient an enhancer which preferentially enhances the enzymatic reactions between LIPG polypeptide and VLDL cholesterol relative to the enzymatic reactions between LIPG polypeptide and HDL cholesterol and apolipoprotein AI.
59. A method for diagnosing a predisposition to low HDL
cholesterol and apolipoprotein AI levels comprising obtaining a tissue sample from a patient and measuring the level of LIPG polypeptide in said sample.
cholesterol and apolipoprotein AI levels comprising obtaining a tissue sample from a patient and measuring the level of LIPG polypeptide in said sample.
60. The method of Claim 59 wherein said tissue is blood.
61. The method of Claim 60 wherein the level of LIPG
polypeptide in said sample is measured by an immunoassay.
polypeptide in said sample is measured by an immunoassay.
62. The method of Claim 59 wherein the levels of LIPG
polypeptide are measured by measuring the levels of LIPG
mRNA.
polypeptide are measured by measuring the levels of LIPG
mRNA.
63. A method for determining whether a test compound can inhibit the enzymatic reaction between the LIPG
polypeptide and HDL cholesterol and apolipoprotein AI
comprising: (A) comparing the level of HDL cholesterol and apolipoprotein AI in a first sample comprising: (1) HDL
cholesterol and apolipoprotein AI, (2) LIPG polypeptide, and (3) said test compound with the level of HDL cholesterol and apolipoprotein AI in another sample comprising: (4) HDL
cholesterol and apolipoprotein AI, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in inhibiting the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein AI by observing whether or not the first sample has a higher level of HDL cholesterol and apolipoprotein AI than that of said other sample.
polypeptide and HDL cholesterol and apolipoprotein AI
comprising: (A) comparing the level of HDL cholesterol and apolipoprotein AI in a first sample comprising: (1) HDL
cholesterol and apolipoprotein AI, (2) LIPG polypeptide, and (3) said test compound with the level of HDL cholesterol and apolipoprotein AI in another sample comprising: (4) HDL
cholesterol and apolipoprotein AI, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in inhibiting the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein AI by observing whether or not the first sample has a higher level of HDL cholesterol and apolipoprotein AI than that of said other sample.
64. A method for determining whether a test compound can enhance the enzymatic reaction between the LIPG
polypeptide and VLDL cholesterol comprising: (A) comparing the level of VLDL cholesterol in a first sample comprising:
(1) VLDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of VLDL cholesterol in another sample comprising: (4) VLDL cholesterol, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol by observing whether or not the first sample has a lower level of VLDL cholesterol than that of said other sample.
polypeptide and VLDL cholesterol comprising: (A) comparing the level of VLDL cholesterol in a first sample comprising:
(1) VLDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of VLDL cholesterol in another sample comprising: (4) VLDL cholesterol, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol by observing whether or not the first sample has a lower level of VLDL cholesterol than that of said other sample.
65. A method for determining whether a test compound can enhance the enzymatic reaction between the LIPG
polypeptide and LDL cholesterol comprising: (A) comparing the level of LDL cholesterol in a first sample comprising: (1) LDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of LDL cholesterol in another sample comprising: (4) LDL cholesterol, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and LDL cholesterol by observing whether or not the first sample has a lower level of LDL cholesterol than that of said other sample.
polypeptide and LDL cholesterol comprising: (A) comparing the level of LDL cholesterol in a first sample comprising: (1) LDL cholesterol, (2) LIPG polypeptide, and (3) said test compound with the level of LDL cholesterol in another sample comprising: (4) LDL cholesterol, and (5) LIPG polypeptide;
and (B) identifying whether or not said test compound is effective in enhancing the enzymatic reaction between the LIPG polypeptide and LDL cholesterol by observing whether or not the first sample has a lower level of LDL cholesterol than that of said other sample.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
| US09/277,401 | 1999-03-26 | ||
| PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2363486A1 true CA2363486A1 (en) | 2000-10-05 |
| CA2363486C CA2363486C (en) | 2012-12-18 |
Family
ID=23060703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2363486A Expired - Fee Related CA2363486C (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1171078A4 (en) |
| JP (1) | JP2002540127A (en) |
| KR (2) | KR100887164B1 (en) |
| AU (1) | AU776684B2 (en) |
| BR (1) | BR0009333A (en) |
| CA (1) | CA2363486C (en) |
| HK (1) | HK1043309A1 (en) |
| IL (2) | IL145526A0 (en) |
| MX (1) | MXPA01009727A (en) |
| NO (2) | NO331779B1 (en) |
| NZ (2) | NZ514350A (en) |
| WO (1) | WO2000057837A2 (en) |
| ZA (1) | ZA200107598B (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| JP6091752B2 (en) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO |
| US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
| DK2396038T3 (en) | 2009-02-12 | 2016-02-01 | Curna Inc | TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF |
| EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| CA2755404C (en) | 2009-03-17 | 2020-03-24 | Joseph Collard | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| CN102803492B (en) | 2009-05-06 | 2016-06-29 | 库尔纳公司 | TTP relevant disease is treated for the natural antisense transcript of triple four proline (TTP) by suppression |
| EP2427553A4 (en) | 2009-05-06 | 2012-11-07 | Opko Curna Llc | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| EP2427554B1 (en) | 2009-05-08 | 2016-11-16 | CuRNA, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| KR101704988B1 (en) | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| ES2629339T3 (en) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1 |
| KR101801404B1 (en) | 2009-06-16 | 2017-12-20 | 큐알엔에이, 인크. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| ES2618894T3 (en) | 2009-06-24 | 2017-06-22 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO THE RECEIVER OF THE TUMOR NECROSIS FACTOR 2 (TNFR2) BY INHIBITION OF THE ANTISENTED NATURAL TRANSCRIPT FOR TNFR2 |
| CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| KR101802536B1 (en) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
| US9044493B2 (en) | 2009-08-11 | 2015-06-02 | Curna, Inc. | Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin |
| CA2771228C (en) | 2009-08-21 | 2020-12-29 | Opko Curna, Llc | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| DK2480669T3 (en) | 2009-09-25 | 2018-02-12 | Curna Inc | TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY |
| RU2639550C2 (en) | 2009-12-16 | 2017-12-21 | Курна, Инк. | Treatment of diseases connected with site-1 membrane-impacted peptidase of transcription factors (mbtps1), by inhibiting natural antisense transcript to mbtps1 |
| JP6031356B2 (en) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー，インコーポレイテッド | Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2. |
| US8940708B2 (en) | 2009-12-23 | 2015-01-27 | Curna, Inc. | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
| EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| KR101853508B1 (en) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
| RU2016115782A (en) | 2009-12-31 | 2018-11-28 | Курна, Инк. | TREATMENT OF DISEASES ASSOCIATED WITH THE SUBSTRATE OF THE INSULIN 2 RECEPTOR (IRS2) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND THE TRANSCRIPTION FACTOR E3 (TFE3) |
| KR101878501B1 (en) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
| DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
| ES2671877T3 (en) | 2010-01-25 | 2018-06-11 | Curna, Inc. | Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1 |
| KR101838308B1 (en) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| RU2612884C2 (en) | 2010-04-02 | 2017-03-13 | Курна, Инк. | Treatment of diseases associated with colonystimulating factor 3 (csf3) by inhibition of natural antisense transcript to csf3 |
| JP5978203B2 (en) | 2010-04-09 | 2016-08-24 | カッパーアールエヌエー，インコーポレイテッド | Treatment of fibroblast growth factor (FGF21) fibroblast growth factor FGF21) related diseases by inhibition of natural antisense transcripts against FGF21 |
| KR101915115B1 (en) | 2010-05-03 | 2018-11-05 | 큐알엔에이, 인크. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
| NO2576784T3 (en) | 2010-05-26 | 2018-04-14 | ||
| RU2585229C2 (en) | 2010-05-26 | 2016-05-27 | Курна, Инк. | Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1 |
| PT2585596T (en) | 2010-06-23 | 2021-03-23 | Curna Inc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| WO2012009402A2 (en) | 2010-07-14 | 2012-01-19 | Opko Curna Llc | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
| CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
| CN103459599B (en) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG |
| CA2838588C (en) | 2011-06-09 | 2021-09-14 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
| WO2013036403A1 (en) | 2011-09-06 | 2013-03-14 | Curna, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| KR20140136488A (en) | 2012-03-15 | 2014-11-28 | 큐알엔에이, 인크. | Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| CN102628060A (en) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | Production method of low-fat milk |
| WO2014069651A1 (en) * | 2012-11-05 | 2014-05-08 | 塩野義製薬株式会社 | Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance |
| JP6304775B2 (en) | 2013-03-14 | 2018-04-04 | 塩野義製薬株式会社 | Monoclonal antibodies that inhibit the enzymatic activity of vascular endothelial lipase |
| TWI734410B (en) | 2014-09-11 | 2021-07-21 | 日商塩野義製藥股份有限公司 | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240277861A1 (en) * | 2021-07-26 | 2024-08-22 | Purotech Bio, Inc. | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994013791A1 (en) * | 1992-12-04 | 1994-06-23 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
| EP0948609B1 (en) * | 1996-12-06 | 2005-03-16 | Aventis Pharmaceuticals Inc. | Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| AU1941899A (en) * | 1997-12-19 | 1999-07-12 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ531180A (en) | 2005-06-24 |
| EP1171078A2 (en) | 2002-01-16 |
| NZ514350A (en) | 2004-12-24 |
| WO2000057837A8 (en) | 2001-09-27 |
| CA2363486C (en) | 2012-12-18 |
| IL145526A0 (en) | 2002-06-30 |
| EP1171078A4 (en) | 2002-11-06 |
| WO2000057837A2 (en) | 2000-10-05 |
| NO20100214L (en) | 2001-11-21 |
| WO2000057837A3 (en) | 2001-01-25 |
| JP2002540127A (en) | 2002-11-26 |
| NO20014657D0 (en) | 2001-09-25 |
| KR100887164B1 (en) | 2009-03-10 |
| NO20014657L (en) | 2001-11-21 |
| NO331784B1 (en) | 2012-03-26 |
| WO2000057837A9 (en) | 2001-10-18 |
| ZA200107598B (en) | 2003-05-28 |
| NO331779B1 (en) | 2012-03-26 |
| BR0009333A (en) | 2002-01-08 |
| KR20020029651A (en) | 2002-04-19 |
| HK1043309A1 (en) | 2002-09-13 |
| MXPA01009727A (en) | 2002-07-22 |
| AU3918700A (en) | 2000-10-16 |
| IL145526A (en) | 2010-11-30 |
| AU776684B2 (en) | 2004-09-16 |
| KR20050044812A (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2363486A1 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
| Francis-Lang et al. | Multiple mechanisms of interference between transformation and differentiation in thyroid cells | |
| Faustinella et al. | Catalytic triad residue mutation (Asp156—-Gly) causing familial lipoprotein lipase deficiency. Co-Inheritance with a nonsense mutation (Ser447—-Ter) in a Turkish family | |
| US20060211020A1 (en) | Methods for the diagnosis, prognosis and treatment of metabolic syndrome | |
| US20110117562A1 (en) | Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) | |
| JP2002540127A5 (en) | ||
| US6974672B2 (en) | Gene amplification in cancer | |
| US20130090370A1 (en) | Apoptosis inducer for cancer cell | |
| Gergs et al. | On the role of junctin in cardiac Ca2+ handling, contractility, and heart failure | |
| AU2020399633A1 (en) | Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases | |
| WO2002064839A2 (en) | Methods for the diagnosis and treatment of tumors employing the hepsin gene | |
| CA2141847A1 (en) | Ptp-d subfamily of protein tyrosine phosphatases | |
| US8288094B2 (en) | APOBEC3 mediated DNA editing | |
| JP4033490B2 (en) | Phosphatase modulator | |
| CN116287272B (en) | Application of PRDX5 in diagnosis and treatment of glioma | |
| Stayner et al. | Cloning and Characterization of the Human PAX2Promoter | |
| Medley et al. | Dictyostelium myosin-II heavy-chain kinase A is activated by autophosphorylation: studies with Dictyostelium myosin-II and synthetic peptides | |
| Luo et al. | Calcineurin enhances acetylcholinesterase mRNA stability during C2-C12 muscle cell differentiation | |
| US20030175763A1 (en) | Identification of an amplified gene and target for drug intervention | |
| Vanegas et al. | Novel COL6A1 splicing mutation in a family affected by mild Bethlem myopathy | |
| US20050059011A1 (en) | Amplification and overexpression of oncogenes | |
| Cmarik et al. | Preferential primary‐response gene expression in promotion‐resistant versus promotion‐sensitive JB6 cells | |
| US20100291550A1 (en) | Methods and compositions for modulating hair growth | |
| Saifudeen et al. | A mutation in the 5′ untranslated region of the human α-galactosidase A gene in high-activity variants inhibits specific protein binding | |
| Barzon et al. | HSV-TK/IL-2 gene therapy for glioblastoma multiforme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160324 |